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Summary
Background Human parainfluenza virus (hPIV) is a common virus in childhood acute lower respiratory infections 
(ALRI). However, no estimates have been made to quantify the global burden of hPIV in childhood ALRI. We aimed 
to estimate the global and regional hPIV-associated and hPIV-attributable ALRI incidence, hospital admissions, and 
mortality for children younger than 5 years and stratified by 0–5 months, 6–11 months, and 12–59 months of age.
Methods We did a systematic review of hPIV-associated ALRI burden studies published between Jan 1, 1995, and 
Dec 31, 2020, found in MEDLINE, Embase, Global Health, Cumulative Index to Nursing and Allied Health Literature, 
Web of Science, Global Health Library, three Chinese databases, and Google search, and also identified a further 
41 high-quality unpublished studies through an international research network. We included studies reporting 
community incidence of ALRI with laboratory-confirmed hPIV; hospital admission rates of ALRI or ALRI with 
hypoxaemia in children with laboratory-confirmed hPIV; proportions of patients with ALRI admitted to hospital with 
laboratory-confirmed hPIV; or in-hospital case–fatality ratios (hCFRs) of ALRI with laboratory-confirmed hPIV. We 
used a modified Newcastle-Ottawa Scale to assess risk of bias. We analysed incidence, hospital admission rates, and 
hCFRs of hPIV-associated ALRI using a generalised linear mixed model. Adjustment was made to account for the 
non-detection of hPIV-4. We estimated hPIV-associated ALRI cases, hospital admissions, and in-hospital deaths using 
adjusted incidence, hospital admission rates, and hCFRs. We estimated the overall hPIV-associated ALRI mortality 
(both in-hospital and out-hospital mortality) on the basis of the number of in-hospital deaths and care-seeking for 
child pneumonia. We estimated hPIV-attributable ALRI burden by accounting for attributable fractions for hPIV in 
laboratory-confirmed hPIV cases and deaths. Sensitivity analyses were done to validate the estimates of overall hPIV-
associated ALRI mortality and hPIV-attributable ALRI mortality. The systematic review protocol was registered on 
PROSPERO (CRD42019148570).
Findings 203 studies were identified, including 162 hPIV-associated ALRI burden studies and a further 41 high-quality 
unpublished studies. Globally in 2018, an estimated 18·8 million (uncertainty range 12·8–28·9) ALRI cases, 
725 000 (433 000–1 260 000) ALRI hospital admissions, and 34 400 (16 400–73 800) ALRI deaths were attributable to 
hPIVs among children younger than 5 years. The age-stratified and region-stratified analyses suggested that about 
61% (35% for infants aged 0–5 months and 26% for 6–11 months) of the hospital admissions and 66% (42% for 
infants aged 0–5 months and 24% for 6–11 months) of the in-hospital deaths were in infants, and 70% of the in-
hospital deaths were in low-income and lower-middle-income countries. Between 73% and 100% (varying by outcome) 
of the data had a low risk in study design; the proportion was 46–65% for the adjustment for health-care use, 
59–77% for patient groups excluded, 54–93% for case definition, 42–93% for sampling strategy, and 67–77% for test 
methods. Heterogeneity in estimates was found between studies for each outcome. 
Interpretation We report the first global burden estimates of hPIV-associated and hPIV-attributable ALRI in young 
children. Globally, approximately 13% of ALRI cases, 4–14% of ALRI hospital admissions, and 4% of childhood ALRI 
mortality were attributable to hPIV. These numbers indicate a potentially notable burden of hPIV in ALRI morbidity 
and mortality in young children. These estimates should encourage and inform investment to accelerate the 
development of targeted interventions.
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Introduction
Acute lower respiratory infection (ALRI) is one of the 
leading causes of morbidity and mortality in children 
globally, accounting for 10% of mortality in children 
younger than 5 years in 2017.1 Human parainfluenza 
virus (hPIV), primarily from four major serotypes 
(hPIV-1 to hPIV-4), usually causes epidemics in the 
spring and early summer. hPIV can cause ALRI and 
more severe infections in young children, leading to a 
considerable disease burden.2,3
Previous systematic reviews have estimated that hPIV 
could be detected in 2·7–5·8% of ALRI cases in children 
younger than 5 years, but the estimates were either 
developed on the basis of a small number of studies or 
for the population of only one country.4,5 Results from 
pooled analyses have shown evidence for the causal 
attribution of hPIV, and estimated that 43–87% of 
ALRI cases with laboratory-confirmed hPIV in children 
younger than 5 years are attributable to hPIV.6,7 There are 
no licensed hPIV vaccines or antiviral treatments.8 A few 
hPIV-3 candidate vaccines are under development, and 
have been assessed in phase 1 and 2 trials showing safety 
and immunogenicity in seronegative children older than 
6 months.9–11 hPIV-1 and hPIV-2 candidate vaccines are 
also under development.12–14
Estimates have not been made to quantify the global 
burden of hPIV in children younger than 5 years. 
Thus, we estimated the global and regional number 
of hPIV-associated ALRI cases, hospital admissions, and 
deaths by age bands (ie, 0–5 months, 6–11 months, and 
12–59 months) among children younger than 5 years 
for 2018. We also estimated the global burden of ALRI 
that is attributable to hPIV by accounting for the causal 
attribution of hPIV. These estimates could help to 
identify age groups that are at a high risk of severe hPIV 
respiratory infections, and guide health investment 
priorities, resource allocation, and development of 
targeted pharmaceutical and non-pharmaceutical 
intervention strategies.
Methods
Systematic review, definitions, and assessment of risk 
of bias
We did a systematic review of hPIV-associated ALRI 
burden in children younger than 5 years (appendix 
pp 5, 6). We searched MEDLINE, Embase, Global Health, 
Cumulative Index to Nursing and Allied Health 
Literature, Web of Science, Global Health Library, 
three Chinese databases (China National Knowledge 
Infrastructure, Wanfang, and Chongqing VIP), and 
Google search (for grey literature) for studies published 
between Jan 1, 1995, and Dec 31, 2020. We also contacted 
authors who might have relevant data, especially 
incidence, hospital admission rates, and in-hospital 
case–fatality ratios (hCFR) data. Several of these authors 
agreed to share more detailed and recent data (we 
included these in the research network). We used the 
terms and related words “parainfluenza virus” AND 
“acute lower respiratory infections” AND “burden” AND 
“children”. No language or publication restrictions were 
applied (languages other than English or Chinese were 
translated with Google translate), and three reviewers 
Research in context
Evidence before this study
Human parainfluenza virus (hPIV), including four major 
serotypes, is commonly detected in childhood acute lower 
respiratory infections (ALRI). Results from multi-country 
pneumonia case-control studies show that hPIV is one of the 
leading causative viruses of childhood ALRI. Two meta-analyses 
estimated that hPIV could be detected in 2·7–5·8% of children 
younger than 5 years admitted to hospital for ALRI. 
The estimates were either developed on the basis of a small 
number of studies or for a specific country. No estimates have 
been made to quantify the global burden of ALRI because of 
hPIV among children younger than 5 years, or by narrow age 
bands. We searched PubMed for studies published between 
Jan 1, 1995, and May 25, 2021, which reported the global 
burden of hPIV, using the search terms “(parainfluenza OR PIV) 
AND (global) AND (child OR infant)”.
Added value of this study
We did a systematic review of 203 studies with data on 
hPIV-associated ALRI community incidence rates, hospital 
admission rates, proportion of laboratory-confirmed hPIV 
among ALRI cases admitted to hospital, and in-hospital 
case–fatality ratios, including 41 high-quality unpublished 
studies that provided data by narrow age bands among children 
younger than 5 years, and 45 studies from low-income and 
lower middle-income countries. We estimated that, in 2018, 
approximately 18·8 million (uncertainty range [UR] 12·8–28·9) 
ALRI cases, 725 000 (UR 433 000–1 260 000) ALRI hospital 
admissions, and 34 400 (UR 16 400–73 800) ALRI deaths were 
attributable to hPIV globally among children younger than 
5 years. When analysed in the context of all-cause ALRI burden 
estimates, hPIV accounts for 13% of ALRI cases, 4–14% of ALRI 
hospital admissions, and 4% of ALRI mortality. Similar to other 
respiratory viruses, a larger proportion of hPIV hospital 
admissions (61%) and in-hospital deaths (66%) occurred in 
infants younger than 1 year. 
Implications of all the available evidence
Our systematic review provides the first global burden estimates 
of hPIV-associated and hPIV-attributable ALRI among children 
younger than 5 years, and estimates by narrow age groups. 
These burden estimates show the role of hPIV in causing child 
ALRI morbidity and mortality, and should inform investment to 
accelerate the development of targeted interventions.
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(XW, YL, and KAM) screened the titles and abstracts for 
eligibility. For potentially eligible studies, reviewers 
screened full-text articles for final inclusion, and extracted 
eligible data independently. Disagreements were resolved 
by discussion between reviewers. For datasets that over-
lapped in study population, location, and period, we 
included either the more detailed dataset (eg, stratified 
by finer age groups) or the more recent version. We 
supplemented the data from published studies with 
additional high-quality unpublished data (from ongoing 
studies or the re-analysis of previously published studies) 
using agreed standard approaches and definitions within 
the Respiratory Virus Global Epidemiology Network.15
We reported any of these data for children younger 
than 5 years: community incidence of ALRI (clinical 
pneumonia, according to the 2005 WHO Integrated 
Management of Childhood Illnesses)16 with laboratory-
confirmed hPIV (ie, molecular test, culture, and antigen 
detection test); hospital admission rates of ALRI (a 
physician-confirmed diagnosis of ALRI) or ALRI with 
hypoxaemia in children with laboratory-confirmed hPIV; 
proportion of laboratory-confirmed hPIV among ALRI 
cases admitted to hospital; or hCFRs of ALRI with 
laboratory-confirmed hPIV. Details of case definitions 
are in the appendix (pp 3, 4).
Studies had to use a clear case definition for 
specimen collection and testing, and studies that 
reported incidence and hospital admission rate data had 
to show data for at least 1 complete calendar year (or at 
least one full season if in a temperate region with 
defined hPIV seasons). We included hCFR data for any 
length of study period. We included data on the 
proportion of hPIV positives if they were from at least 
1 full calendar year. We excluded studies without a 
clear denominator population at risk (limited to those 
reporting incidence and hospital admission rate data), 
those in which hPIV was detected only in samples that 
were tested negative for other viruses, those which 
reported modelled burden esti mates, those in which 
hPIV infections were diagnosed on the basis of serology 
alone, or those which only included population 
subgroups with high-risk conditions.
The risk of bias in included studies was assessed using 
a modified Newcastle-Ottawa Scale, containing seven 
domains: study design, adjustment for health-care use, 
patient groups excluded, case definition, sampling 
strategy, diagnostic testing, and hypoxaemia ascertain-
ment (appendix pp 30, 31).17
Statistical analysis
Our approach to burden esti mation, including main 
analyses and sensitivity analyses, is summarised in the 
appendix (p 9). We estimated hPIV-associated ALRI cases, 
hospital admissions, and in-hospital deaths using a 
strategy similar to our previous analysis.15 We pooled 
incidence rates, hospital admission rates, and hCFRs of 
hPIV-associated ALRI using a generalised linear mixed 
model.18 Differences between studies were anticipated, 
thus we used the generalised linear mixed model that 
accounts for the differences. Before meta-analysis, for the 
incidence rate and hospital admission rate, we scaled 
the population-at-risk for the level of testing per study 
where available before meta-analyses (appendix p 28). Not 
all studies reported data for hPIV-4, so we adjusted the 
hPIV case number to account for missing hPIV-4 cases in 
incidence and hospital admission rates and proportion 
positives on the basis of an estimated proportion of 
hPIV-4 in all hPIV cases (12% based on 24 studies; 
appendix p 17). Similarly, we adjusted hCFR estimates to 
account for missing hPIV-4 hospital admis sions and 
deaths on the basis of estimated proportion and hCFRs of 
four hPIV types (appendix p 18).
After meta-analyses, we chose the Monte Carlo 
Simulation to estimate morbidity burden because it 
allows us to combine meta-estimates and population 
estimates (UN population estimates for 2018).19 The 
median value of 10 000 samples simulated from a 
log–normal distribution was used as the point burden 
estimate and the 2∙5th and 97∙5th percentiles as the 
95% uncertainty range (UR). In the main analysis, we 
reported estimates stratified by three non-overlapping age 
bands (0–5 months, 6–11 months, and 12–59 months) and 
by 2018 child mortality settings (low or high, with a cut-
off point of the median value of the mortality rate of those 
younger than 5 years) for each outcome where available.20 
The global results were calculated as the sum of age-specific 
and region-specific estimates. The numbers of cases were 
rounded to the nearest thousand and the number of 
deaths to the nearest hundred. In community settings, 
we reported the incidence for the overall age band 
(0–59 months) because data were insufficient to allow 
disaggregation by narrower age bands. We imputed the 
numbers of cases for 0–59 months using a multiple 
imputation approach if data were reported for other age 
bands (eg, 0–11 months; appendix p 28).15
We estimated the number of hPIV-associated in-
hospital ALRI deaths by combining the estimates 
of hospital admissions and hCFRs of hPIV-associated 
ALRI.21 The adjusted hospital admissions and hCFRs 
(accounting for missing hPIV-4) were used in the analysis. 
Similar to morbidity estimation, the global estimates of 
mortality were calculated as the sum of the estimates by 
the three age groups and by child mortality settings.
We estimated the number of overall hPIV-associated 
ALRI deaths by combining the estimates of hPIV-
associated in-hospital deaths and the ratio of overall 
deaths to in-hospital deaths (labelled as an inflation 
factor). Details of data sources and analyses of the 
inflation factor have been described previously (appendix 
pp 19, 20).15 Briefly, the median ratio of overall ALRI 
deaths to in-hospital ALRI deaths at eight sites in 
six countries with high child mortality was extrapolated to 
other countries with high child mortality. For settings 
with low child mortality, the reciprocal of the proportion 
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of children with pneumonia symptoms who received 
care, measured in Multiple Indicator Cluster Surveys, 
Demographic and Health Surveys, and other national 
surveys, was used as a proxy for inflation factor.22 The 
median value was extrapolated to other countries with 
low child mortality without data.
On the basis of hPIV-associated ALRI burden esti-
mates, we estimated the ALRI burden attributable to 
hPIV by accounting for the attributable fraction of 
hPIV in hPIV-associated ALRI cases and deaths. Two 
pooled analyses of multi-country data showed that 
the attributable fraction of hPIV-associated ALRI cases 
varied by type;6,7 we estimated the average attributable 
fraction of hPIV cases and hospital admissions using 
type-specific attributable fraction estimates and the 
pooled proportion of four hPIV-type cases (appendix 
p 22). The attributable fraction of hPIV-associated ALRI 
deaths was calculated using the attributable fraction of 
hPIV-associated ALRI cases and the ratio between the 
hCFRs of hPIV-positive ALRI and hPIV-negative ALRI. 
We assumed that the hCFR of hPIV-negative ALRI was 
equal to the hCFR of hPIV-positive ALRI that were not 
deemed attributable to hPIV (appendix pp 23, 24).
Sensitivity analyses
For hPIV-associated ALRI morbidity and in-hospital 
deaths, we reported estimates by country development 
regions according to UNICEF definitions and by World 
Bank income levels (low-income and lower-middle-
income, upper-middle-income, and high-income) in 
sensitivity analyses.23,24 Additionally, we estimated the 
range of hPIV-associated ALRI hospital admissions by 
applying the proportion of those positive for hPIV in 
ALRI hospital admissions and the estimates of all-cause 
ALRI hospital admissions among children younger 
5 years for 2015–16 (appendix p 13).25,26 We estimated the 
overall hPIV-associated ALRI mortality for settings with 
high child mortality in a sensitivity analysis by applying 
the proportion of ALRI deaths positive for hPIV to the 
number of ALRI deaths among children younger than 
5 years for 2017.1 The proportion of ALRI deaths positive 
for hPIV was estimated using data from 12 hospital-
based studies retrieved with our systematic review 
(including five PERCH sites) from high mortality burden 
settings in which at least 90% of ALRI cases were tested 
and at least five ALRI deaths were identified during the 
study period (appendix p 21). In the sensitivity analysis, 
the hPIV-attributable ALRI mortality for settings with 
high child mortality was estimated using another 
approach by applying the proportion of hPIV-attributable 
ALRI deaths to the number of ALRI deaths among 
children younger than 5 years. The proportion of hPIV-
attributable ALRI deaths was estimated using data in the 
period from December, 2016, to October, 2019, from the 
Child Health and Mortality Prevention Surveillance (also 
known as CHAMPS; appendix p 25).27
We report the estimates from the main analysis. 
Sensitivity results are in the appendix (pp 10–16, 18, 
21, 25), as are details of the included studies (pp 39–58). 
All analyses were done in R (version 3.6.1).28,29 This 
study was done and reported in accordance with the 
Guidelines for Accurate and Transparent Health 
Estimates Reporting recommendations (appendix p 72).30 
The systematic review protocol was registered on 
PROSPERO (CRD42019148570).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
We identified 203 studies with data on hPIV-associated 
ALRI community incidence rates (13 studies), hospital 
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Figure: Flow diagram for study selection for hPIV-associated ALRI burden
A study was defined as a dataset from one site in one published paper or from one research group in the network. 
Some studies provided more than one type of data, so the sum of studies across types was larger than the total 




hPIV-associated severe ALRI (n=5) 
Hospital admission rates:
hPIV-associated ALRI (n=38);
hPIV-associated ALRI with 
hypoxaemia (n=13)
Studies with data on proportion 
of laboratory-confirmed hPIV 
among ALRI cases admitted to 
hospital (n=168) and hCFRs 
(n=58)
5285 records identified through database search
3888 records screened
1258 full-text articles assessed for eligibility
157 papers included (162 studies)
1597 duplicates removed
2630 records excluded as not relevant to topic 
41 studies from the collaboration network 
200 records identified through other sources
1101 full-text articles excluded
622 no data for children aged 0–59 months
167 irrelevant to hPIV
205 incomplete years or seasons data
83 duplicate data
4 no denominator
6 using model techniques
3 in people with high-risk conditions
10 no full texts
1 unable to translate (Arabic)
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admission rates (38 studies), proportion of those positive 
for hPIV in ALRI hospital admissions (168 studies), and 
hCFRs (58 studies; figure). There were 41 unpublished 
studies from the collaborative network and 162 studies 
from published literature. By World Bank income levels, 
eight studies were from low-income countries, 37 from 
lower-middle-income countries, 109 from upper-middle-
income countries, and 49 from high-income countries. 
The number of studies is summarised in the appendix 
(pp 7–8).
We identified 13 studies with incidence rates of hPIV-
associated ALRI. There were 12 studies with data for 
0–59 months (including imputed data). Seven studies 
reported the rates for before 2010. One study detected 
all four hPIV types, one study only detected hPIV-3, and 
other studies detected hPIV-1 to hPIV-3. The adjusted 
hPIV-associated ALRI incidence rate meta-estimate was 
38·8 (95% CI 30·1–50·2) per 1000 children per year for 
ages 0–59 months for settings with high child mortality, 
and 37·8 (18·5–77·3) per 1000 children per year for 
settings with low child mortality. The high incidence in 
low child mortality settings was mainly driven by two 
Australian studies (one for 1996–99, and the other for 
2010–14). We estimated 26·1 million (UR 17·8–40·1) 
hPIV-associated ALRI cases globally in children younger 
than 5 years (table 1).
There were 38 studies with hPIV-associated ALRI 
hospital admission rates, including 26 studies report-
ing data by three narrow age bands: 0–5 months, 
6–11 months, or 12–59 months. Only nine studies 
reported data for all four hPIV types. The adjusted 
hospital admission rate was higher in infants 
(0–11 months) than children aged 12–59 months across 
World Bank income levels and child mortality settings. 
Particularly in settings with high child mortality, the 
rate was 5·8 (95% CI 3·7–9·2) per 1000 children per year 
for ages 0–5 months, 4·7 (3·2–6·7) for 6–11 months, 
and 0·7 (0·5–1·2) for children aged 12–59 months 
(table 2). In the main analysis (by child mortality settings), 
we estimated 1 007 000 (UR 601 000–1 750 000) hPIV-
associated ALRI hospital admis sions globally in children 
younger than 5 years. Of these hospital admissions, 
35% were in children aged 0–5 months, 26% were in 
children aged 6–11 months, and 39% were in children 
aged 12–59 months.
There were 13 studies reporting hospital admission 
rates for hPIV-associated ALRI with hypoxaemia by 
age band, including nine studies reporting data for all four 
hPIV types. In the analysis stratified by child mortality 
settings, we estimated 162 000 (UR 88 000–779 000) 
hospital admissions for hPIV-associated ALRI with hypox-
aemia (adjusted for missing hPIV-4) in children aged 
0–59 months globally, accounting for 16% of the 
hPIV-associated ALRI hospital admissions.
We identified 58 studies reporting the hCFRs of 
hPIV-associated ALRI in children younger than 5 years, 
including 27 studies with data stratified by three narrow 
age bands. Eight studies did not report data for hPIV-4. 








Low child mortality 
settings
High child mortality 
settings
Global estimates (low 
and high child mortality 
settings)
0–5 months
Number of studies 5 1 0 0 6 ··
Incidence (95% CI)* 43·2 (11·7–146·4) ·· ·· ·· 51·1 (18·1–136·0) ··
ALRI cases (thousands; UR) 1913 (545–6723) ·· ·· ·· 2352 (863–6415) ··
6–11 months
Number of studies 5 1 0 0 6 ··
Incidence (95% CI)* 89·3 (65·7–120·2) ·· ·· ·· 85·7 (66·0–110·6) ··
ALRI cases (thousands; UR) 3920 (2903–5294) ·· ·· ·· 3911 (3025–5056) ··
12–59 months
Number of studies 4 1 0 0 5 ··
Incidence (95% CI)* 28·5 (15·9–50·6) ·· ·· ·· 28·5 (17·9–45·2) ··
ALRI cases (thousands; UR) 9774 (5497–17386) ·· ·· ·· 10 164 (6413–16 115) ··
0–59 months
Number of studies† 7 (3) 1 4 (3) 4 (3) 8 (3) ··
Incidence (95% CI)* 37·7 (27·8–51·0) ·· 37·8 (18·5–77·3) 37·8 (18·5–77·3) 38·8 (30·1–50·2) ··
ALRI cases (thousands; UR) 16 247 (12 013–21 978) ·· 2395 (1176–4880) 8670 (4258–17 664) 17 417 (13 504–22 467) 26 087 (17 762–40 131)
The median value of the 2018 younger than 5 years mortality rate was used as the cutoff point for high child mortality and low child mortality settings. The incidence rate was adjusted to account for the missing 
hPIV-4 (ten studies). In one study, only the hPIV-3 rate was available; the rate was adjusted to account for the missing hPIV-1, hPIV-2, and hPIV-4. For the remaining one study, four types were detected and the 
rate was not adjusted. ALRI=acute lower respiratory infections. hPIV=human parainfluenza virus. UR=uncertainty range. *Incidence (per 1000 children per year) from meta-analyses. †The number in the 
parentheses shows the number of imputed studies. 
Table 1: Estimates of the incidence (per 1000 children per year), and number of hPIV-associated ALRI cases in age groups of children younger than 5 years in 2018, by World Bank income 
level and child mortality setting
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The hCFR meta-estimates did not vary much by age 
band; however, we observed a 1–2-times difference across 
settings. Children in countries with high child mortality 
and in lower-middle-income countries generally had the 
highest hCFRs (2·3–3·6% for high child mortality 
settings; 2·0–3·9% for lower-middle-income countries; 
table 3). We estimated 25 700 (UR 12 000–56 500) 
hPIV-associated in-hospital ALRI deaths in children 
younger than 5 years. Of these deaths, approximately 
42% were in children aged 0–5 months, 24% were in 
children aged 6–11 months, and 34% were in children 
aged 12–59 months (table 3).
We estimated a median inflation factor of 2·2 for settings 
with high child mortality and 1·3 for those with low child 
mortality (appendix p 20). Combining the estimates of 
inflation factors and hPIV-associated in-hospital ALRI 
mortality, we estimated 47 600 (UR 23 400–97 100) overall 
hPIV-associated ALRI deaths in high child mortality 
settings, and 53 000 (25 300–113 500) deaths globally.
We estimated an average attributable fraction of 72% 
for hPIV-associated ALRI cases, and 65% for hPIV-
associated ALRI deaths among children younger than 
5 years (table 4; appendix pp 20–22). Thus, we estimated 
that 18·8 million (UR 12·8–28·9) ALRI cases, 725 000 
(433 000–1 260 000) ALRI hospital admissions, and 34 400 
(16 400–73 800) ALRI deaths could be attributed to hPIV 
in children younger than 5 years globally. There were 
30 900 (UR 15 200–63 100) hPIV-attributable ALRI deaths 
in settings with high child mortality.
We did several sensitivity analyses to estimate hospital 
admissions, in-hospital deaths, and overall deaths of 
hPIV-associated ALRI, as well as hPIV-attributable ALRI 
deaths. For global hPIV-associated ALRI hospital admis-















(low and high 
child mortality 
settings)
hPIV-associated ALRI 0–5 months
Number of studies 7 6 4 7 10 ··
Hospital admission rate (95% CI) 3·8 (1·8–7·8) 5·7 (3·0–10·5) 5·5 (3·1–9·9) 3·6 (1·8–7·0) 5·8 (3·7–9·2) ··
Hospital admissions (thousands; UR) 168 (81–349) 105 (56–196) 35 (20–62) 83 (42–163) 267 (170–420) 350 (212–583)
hPIV-associated ALRI 6–11 months
Number of studies 7 5 3 5 10 ··
Hospital admission rate (95% CI) 3·5 (1·7–7·0) 3·8 (1·9–7·6) 3·5 (1·9–6·5) 2·0 (0·9–4·6) 4·7 (3·2–6·7) ··
Hospital admissions (thousands; UR) 154 (76–311) 70 (35–139) 22 (12–41) 46 (20–104) 214 (149–310) 260 (169–413)
hPIV-associated ALRI 12–59 months
Number of studies 8 8 4 8 12 ··
Hospital admission rate (95% CI) 0·8 (0·4–1·4) 0·8 (0·4–1·6) 0·8 (0·2–2·9) 0·8 (0·3–1·9) 0·7 (0·5–1·2) ··
Hospital admissions (thousands; UR) 274 (147–512) 117 (59–233) 41 (11–153) 147 (59–368) 250 (162–386) 396 (220–753)
hPIV-associated ALRI 0–59 months
Hospital admissions (thousands; UR) 596 (304–1171) 292 (150–569) 98 (42–257) 276 (121–634) 731 (480–1116) 1007 (601–1750)
hPIV-associated ALRI with hypoxaemia 0–5 months
Number of studies 6 3 1 2 7 ··
Hospital admission rate (95% CI) 0·6 (0·3–1·6) 1·8 (1·1–3·0) ·· 0·2 (0·1–0·3) 1·4 (0·8–2·4) ··
Hospital admissions (thousands; UR) 27 (12–61) 33 (20–55) ·· 5 (3–8) 64 (37–111) 69 (40–119)
hPIV-associated ALRI with hypoxaemia 6–11 months
Number of studies 6 3 1 2 7 ··
Hospital admission rate (95% CI) 0·3 (0·1–0·9) 1·0 (0·5–1·8) ·· 0·1 (0·0–0·2) 0·8 (0·5–1·4) ··
Hospital admissions (thousands; UR) 13 (4–39) 18 (10–35) ·· 2 (0–14) 36 (22–61) 39 (22–75)
hPIV-associated ALRI with hypoxaemia 12–59 months
Number of studies 6 6 1 4 8 ··
Hospital admission rate (95% CI) 0·1 (0·1–0·2) 0·1 (0·0–1·2) ·· 0·1 (0·0–4·4) 0·1 (0·1–0·2) ··
Hospital admissions (thousands; UR) 34 (24–48) 15 (1–223) ·· 18 (1–534) 36 (25–50) 54 (26–584)
hPIV-associated ALRI with hypoxaemia 0–59 months
Hospital admissions (thousands; UR) 74 (40–149) 66 (31–313) ·· 25 (4–556) 137 (84–223) 162 (88–779)
The median value of the 2018 younger than 5 years mortality rate was used as the cutoff point for settings with high child mortality and low child mortality. The hospital 
admission rate was adjusted to account for the missing hPIV-4. Hospital admission rates from meta-analyses. ALRI=acute lower respiratory infections. hPIV=human 
parainfluenza virus. UR=uncertainty range.
Table 2: Hospital admission rates (per 1000 children per year), and hospital admissions of hPIV-associated ALRI in age groups of children younger than 
5 years in 2018, by World Bank income level and child mortality setting
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ranged from 986 000 to 1 007 000 in analyses by different 
stratification groups (appendix pp 11, 12); the proportion-
based approach yielded a broader range (ie, from 452 000 
to 1 443 000 admissions; appendix p 13). The point 
estimate of global in-hospital deaths ranged from 25 700 
to 27 800 in children younger than 5 years, and an 
estimated 70% of the global in-hospital deaths occurred 
in lower-middle-income countries (19 400 of 27 800) based 
on the results by World Bank income level (appendix 
pp 14, 15). We estimated 56 100 (UR 36 500–87 400) hPIV-
associated ALRI deaths and 45 500 (24 900–91 700) hPIV-
attributable ALRI deaths in children younger than 5 years 
in settings with high child mortality in sensitivity analyses 
(appendix pp 21, 25).
Between 73% and 100% (varying by outcome) of the 
studies had a low risk in study design, 46–65% of the 
studies had a low risk in adjustment for health-care use, 
59–77% of studies had a low risk in patient groups 
excluded, 54–93% of studies had a low risk in case 
definition, 42–93% of studies had a low risk in sampling 
strategy, and 67–77% of studies had a low risk in test 
methods (appendix p 8). Differences in estimates were 
found for all outcomes (appendix pp 43–44). For example, 
the unadjusted incidence rate of hPIV-associated ALRI 
ranged from 17·3 (95% CI 9·3–31·8) to 56·5 (38·1–82·9) 
per 1000 children per year for ages 0–59 months between 
studies. Hospital admission rates of hPIV-associated 
ALRI ranged from 0·8 (0·1–5·4) to 30·1 (18·2–49·3) per 
1000 children per year for 0–5 months, 0·6 (0·4–0·8) to 
18·1 (9·8–33·4) for 6–11 months, and 0·0 (0·0-1000·0) to 
6·8 (5·3–8·7) for 12–59 months between studies.
Discussion
We report the first global hPIV-associated and hPIV-
attributable ALRI burden estimates among children 
younger than 5 years. A comparison between available all-
cause ALRI burden estimates and our hPIV-specific 
estimates suggests that hPIV could be detected in 19% of 
ALRI cases (26 of 138 million), 6–20% of ALRI hospital 
admissions (1 of 5–16 million), and 7% of ALRI mortality 
(53 000 of 809 000) among children younger than 5 years 
globally.1,25,26 Of note, the number of hPIV-associated ALRI 
cases was developed on the basis of few data, and therefore 
needs to be verified with additional data. hPIV can be 
detected in the upper respiratory tract in healthy children 
and mere isolation does not indicate a causal association 








Low child mortality 
settings
High child mortality 
settings
Global estimates (low 








3·9 (2·1–7·3) 2·4 (1·3–4·6) 0·9 (0·2–3·6) 1·3 (0·6–3·1) 3·6 (2·2–5·8) ··




2·0 (0·5–7·4) 3·8 (2·2–6·6) 1·2 (0·3–4·7) 2·6 (1·0–6·9) 2·3 (0·9–5·8) ··




3·5 (2·2–5·6) 1·9 (0·8–4·1) 0·9 (0·4–1·9) 1·2 (0·7–2·3) 2·8 (1·8–4·4) ··
Deaths (UR) 9600 (4500–20 900) 2200 (800–6400) 400 (100–1700) 1800 (600–5200) 7000 (3800–13 000) 8800 (4400–18 100)
0–59 months
Deaths (UR) 19 400 (7800–50 800) 7400 (3000–18 900) 1000 (200–4100) 4100 (1400–12 400) 21 600 (10 600–44 100) 25 700 (12 000–56 500)
The median value of the 2018 younger than 5 years mortality rate was used as the cutoff point for settings with high child mortality and low child mortality. The in-hospital 
deaths were estimated using adjusted hospital admissions and adjusted hCFRs to account for the missing hPIV-4. hCFR estimates were from meta-analyses. ALRI=acute 
lower respiratory infections. hCFR=In-hospital case-fatality ratio. hPIV=human parainfluenza virus. UR=uncertainty range.
Table 3: hCFR meta-estimates of hPIV-associated ALRI and in-hospital deaths in age groups of children younger than 5 years in 2018, by World Bank 







ALRI cases (millions) 72%‡ 26·1 (17·8–40·1) 18·8 (12·8–28·9)
ALRI hospital admissions (thousands) 72% 1007 (601–1750) 725 (433–1260)
ALRI deaths 65%§ 53 000 (25 300–113 500) 34 400 (16 400–73 800)
ALRI=acute lower respiratory infections. hPIV=human parainfluenza virus. UR=uncertainty range. *The fraction of ALRI 
cases and deaths with laboratory-confirmed hPIV that are attributable to hPIV. †Applying the corresponding 
attributable fraction to the estimates of hPIV–associated burden. ‡The attributable fraction for hPIV–associated ALRI 
cases was calculated using type-specific attributable fraction and prevalence. Details and the references are in the 
appendix (p 19). §The attributable fraction for hPIV-associated ALRI deaths was modelled using the attributable 
fraction for hPIV cases and the ratio of case-fatality between hPIV-attributable cases and hPIV-associated cases. Details 
are in the appendix (pp 20, 21). 
Table 4: Estimates of global number of hPIV-attributable ALRI cases, hospital admissions, and deaths 
among children younger than 5 years in 2018 using attributable fraction of hPIV-associated ALRI
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us to estimate the proportion of ALRI cases in which hPIV 
is isolated and is the probable cause. Estimates from 
this analysis suggested that 13% of ALRI cases (18·8 of 
138·0 million), 4–14% ALRI hospital admissions (0·7 of 
5·0–16·0 million), and 4% of ALRI mortality (34 400 of 
809 000) could be attributed to hPIV. When considered in 
the context of our other virus-specific ALRI burden 
estimates, hPIV-attributable ALRI hospital admissions 
and mortality in children younger than 5 years seem 
higher than for human meta pneumovirus (approxi-
mately 500 000 human metapneumovirus-attributable 
ALRI hospital admissions and 11 000 deaths), but similar 
to that for seasonal influenza virus (approximately 700 000 
influenza virus-attributable ALRI hospital admissions), 
and lower than the burden for respiratory syncytial 
virus.15,21,31 These estimates indicate that hPIV is an 
important virus, in that it is a substantial burden, related 
to ALRI in young children.
Similar to other viruses, a large proportion of the hPIV-
associated ALRI burden occurred in infants younger 
than 1 year (61% of hPIV hospital admissions and 66% of 
hPIV in-hospital deaths), and children in low-income 
and lower-middle-income countries had the highest 
hCFRs.15,21,26 The high burden in infants might reflect 
their immature immune systems and decay of maternal 
antibodies.32,33 Children aged 12–59 months still had high 
hCFRs compared with infants, which might reflect the 
virulence of hPIV and have implications for development 
of prevention strategies. Differences in data availability 
exist for different viruses, and the current hPIV burden 
estimates are based on fewer datapoints than those for 
seasonal influenza virus and respiratory syncytial virus, 
and will probably be refined when more data are available 
in future.
Our global burden estimates were generally robust in 
sensitivity analyses. The estimates for global hPIV-
associated ALRI hospital admissions and in-hospital 
mortality, and overall hPIV-associated ALRI mortality, 
were all similar in different stratification groups and 
other sensitivity analyses (appendix pp 11–15, 21, 25). 
We reported a more conservative estimate of hPIV-
attributable mortality in our main analysis (using the 
attributable fraction approach), and the point estimate 
increased by 47% (30 900/45 500) in settings with high 
child mortality in a sensitivity analysis (appendix p 25). 
We calculated the attributable fraction of hPIV in hPIV-
confirmed cases and deaths using data from two pooled 
analyses, which were mainly from settings with high 
child mortality.6,7 The estimates might have limited the 
representativeness of these data for low child mortality 
settings. The attributable fraction approach, estimated 
using data from case-control studies, indicates the 
probable true burden of hPIV in ALRI. However, making 
a causal inference is a challenge when using data from 
observational studies.
In general, we used the same analytical strategy as 
used previously,15,21 with one adaptation in the current 
analysis to enable us to report burden estimates for the 
four hPIV types based on studies that reported data 
either for three types (hPIV-1 to hPIV-3) or four types. 
Our four hPIV-type ALRI burden estimates were adjusted 
on the basis of two key variables. One variable was the 
proportion of hPIV-4 in all hPIVs (12%), which was 
estimated in a pooled analysis of 24 hospital-based 
studies. We extrapolated this prevalence to community 
settings. There was only one community-based study 
detecting all four types and reporting hPIV-4 in 20% of 
hPIV cases. We consider the extrapolation to improve the 
generalisation of this adjustment, although it might have 
led to a conservative estimate of hPIV-4 associated ALRI 
cases. The second set of variables, hCFRs for four hPIV 
types, was estimated using data from five studies from 
countries with high child mortality. The type-specific 
hCFRs had wide and overlapping confidence intervals, 
especially for hPIV-2 and hPIV-4, reflecting the sub-
stantial variation across studies and limited precision 
because of the small case numbers for the two types. 
Additional data on hPIV type-specific hCFRs might help 
to refine the analyses and estimates.
The wide URs of the burden estimates reflected the 
differences in hPIV epidemiology between populations, 
methodological differences, and paucity of data. As 
shown in the described risk of bias of studies, 
methodological heterogeneity between studies could 
have probably biased our estimates (appendix p 8). hPIV-
associated ALRI hospital admissions could have been 
overestimated in 27% (seven of 26 studies; appendix p 8) 
of hospital admission studies, which adopted broader 
case definitions (eg, patients with ALRI admitted 
to hospital; patients with ALRI or croup admitted 
to hospital). Underdetection (a detection rate of less 
than 90%) was observed in 23% of studies in the analysis 
of hPIV-associated ALRI hospital admissions. We 
adjusted for underdetection as previously described by 
assuming the percent positivity for hPIV was the same in 
those tested and untested, and incorporated differences 
in rates of underdetection between studies in the meta-
analyses of incidence and hospital admission rates.15 We 
did not adjust for underdetection when estimating 
hCFRs; the underdetection could cause an under-
estimation of hCFR estimates, because severe cases and 
deaths are usually less likely to be sampled compared 
with non-severe cases.34 We found a consistent result in 
our data showing that the hCFR in those tested was lower 
than in those untested (appendix p 29). Approximately 
32% (12/38; appendix p 8) of studies with data on 
incidence and hospital admission rates used traditional 
test methods (eg, indirect immuno fluorescence assay, 
culture, and mixed test methods). These traditional test 
methods have a similar specificity but lower sensitivity 
than molecular tests, and thus could result in an 
underestimation of the true burden.35,36 Most hospital-
based studies used nasopharyngeal specimens solely or 
in combination with other respiratory tract specimens 
Articles
www.thelancet.com/lancetgh   Vol 9   August 2021 e1085
(appendix pp 49–51), and it has been reported that 
nasopharyngeal specimens have similar or higher 
sensitivity in detecting hPIV than do other upper 
respiratory tract specimens.37–40 Additionally, the inclusion 
of old data (34% [17 of 50 studies] of the data in the main 
analysis were from the pre-2010 period) could have 
biased our estimates. We chose 2010 as the cutoff because 
more studies have started to use molecular tests since the 
2009 influenza pandemic. The included data suggest 
that approximately 81% (13/16) of hospital-based studies 
used molecular tests since 2010 compared with 50% 
(five of ten studies) before 2010. Estimation of inflation 
factors (and overall hPIV-associated ALRI mortality) 
in this study was based on the same data as we used 
previously (data on care-seeking for non-specific 
pneumonia symptoms and deaths) and so was susceptible 
to similar potential limitations and assumptions 
(appendix p 19).15
In general, our hPIV ALRI burden estimates, derived 
from laboratory-confirmed data, probably show the lower 
limit of the true burden of hPIV because of the challenge 
in systematically diagnosing and detecting hPIV infections, 
and many factors that can affect test results and lead to a 
false negative diagnosis. Additionally, the estimates of 
hospital admissions have probably underestimated the 
potential burden of hPIV-associated ALRI on health-care 
services, especially in regions with a low health-care 
capacity and poor access to care. Nevertheless, our hPIV-
associated and hPIV-attributable ALRI burden estimates 
suggest that hPIV is a notable virus in childhood ALRI. 
These estimates should help to guide health investment 
priorities and resource allocation. By raising awareness 
of the disease and health-care burden these estimates 
might also encourage and inform investment to accelerate 
the development of targeted prevention and treatment 
interventions.
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